Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | TLR4 | O00206 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14138017 | 0.83 | TLR4 (0.39) | TLR4MAPTCYP2C9ALDH1A1LMNA | |
| SCHEMBL6380895 | 0.80 | ALDH1A1 (0.53) | CYP1A2MAPTCYP2C9ALDH1A1LMNA | |
| SCHEMBL13593723 | 0.79 | MAPT (0.47) | CYP1A2TLR4MAPTALDH1A1LMNA | |
| SCHEMBL8052103 | 0.78 | FFAR3 (0.43) | TLR4MAPTCYP2C9HSD11B1ALDH1A1 | |
| SCHEMBL6523852 | 0.77 | MAPT (0.47) | TLR4MAPTCYP2C9ALDH1A1LMNA | |
| SCHEMBL9442491 | 0.77 | TLR4 (0.43) | TLR4MAPTCYP2C9HSD11B1ALDH1A1 | |
| SCHEMBL9442484 | 0.77 | TLR4 (0.43) | TLR4MAPTCYP2C9HSD11B1ALDH1A1 | |
| SCHEMBL8729065 | 0.77 | TLR4 (0.43) | TLR4MAPTCYP2C9HSD11B1ALDH1A1 | |
| SCHEMBL6523850 | 0.77 | MAPT (0.47) | TLR4MAPTCYP2C9ALDH1A1LMNA | |
| SCHEMBL6523843 | 0.77 | MAPT (0.47) | TLR4MAPTCYP2C9ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9255223-B2 | Polymerizable compounds and liquid crystal media | MERCK PATENT GMBH (DE) | 2016-02-09 | — | — | US | disclosed |
| US-9255223-B2 | Polymerizable compounds and liquid crystal media | MERCK PATENT GMBH (DE) | 2016-02-09 | — | — | US | disclosed |
| US-20120298916-A1 | POLYMERIZABLE COMPOUNDS AND LIQUID CRYSTAL MEDIA | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-11-29 | — | — | US | disclosed |
| US-20120298916-A1 | POLYMERIZABLE COMPOUNDS AND LIQUID CRYSTAL MEDIA | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-11-29 | — | — | US | disclosed |
| US-20120298916-A1 | POLYMERIZABLE COMPOUNDS AND LIQUID CRYSTAL MEDIA | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-11-29 | — | — | US | disclosed |
| WO-2011088882-A1 | POLYMERIZABLE COMPOUNDS AND LIQUID CRYSTAL MEDIA | MERCK PATENT GMBH (DE) | 2011-07-28 | — | — | WO | disclosed |
| WO-2011088882-A1 | POLYMERIZABLE COMPOUNDS AND LIQUID CRYSTAL MEDIA | MERCK PATENT GMBH (DE) | 2011-07-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120298916-A1 | POLYMERIZABLE COMPOUNDS AND LIQUID CRYSTAL MEDIA | RCC1, CCNB2, CCNB1 | CYP1A2 1390/4885TLR4 4114/4885MAPT 101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.